Yamada Hiroyuki, Ohtsuru Shigeru
Department of Primary Care and Emergency Medicine, Graduate School of Medicine, Kyoto University, 54 Shogoin-kawaharacho, Sakyo-ku, Kyoto, 6068507, Japan.
Department of Nephrology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
J Intensive Care. 2021 Dec 11;9(1):74. doi: 10.1186/s40560-021-00586-0.
Coronavirus disease 2019 (COVID-19) threatened human lives worldwide since first reported. The current challenge for global intensivists is to establish an effective treatment for severe COVID-19. Blood purification has been applied to the treatment of various critical illnesses. Theoretically, its technique also has an enormous possibility of treating severe COVID-19 in managing inflammatory cytokines and coagulopathy. Recent clinical studies have revealed the positive clinical effect of therapeutic plasma exchange. Other studies have also indicated the considerable potential of other blood purification techniques, such as Cytosorb, AN69 surface-treated membrane, and polymyxin b hemoperfusion. Further research is needed to elucidate the actual effects of these applications.
自首次报告以来,2019冠状病毒病(COVID-19)在全球范围内威胁着人类生命。目前,全球重症监护医生面临的挑战是为重症COVID-19建立有效的治疗方法。血液净化已应用于各种危重病的治疗。从理论上讲,其技术在治疗重症COVID-19的炎症细胞因子和凝血病方面也有巨大的可能性。最近的临床研究揭示了治疗性血浆置换的积极临床效果。其他研究也表明了其他血液净化技术的巨大潜力,如Cytosorb、AN69表面处理膜和多粘菌素B血液灌流。需要进一步研究以阐明这些应用的实际效果。